26530-89-2

Usage

Uses

Used in Pharmaceutical Research and Development:
1-BENZYL-1H-BENZOIMIDAZOL-5-YLAMINE TRIHYDROCHLORIDE is used as a precursor in the synthesis of new drugs for its antitumor and antiviral properties, making it valuable in the fight against cancer and viral infections.
Used in Neurodegenerative Disease Treatment:
In the medical field, 1-BENZYL-1H-BENZOIMIDAZOL-5-YLAMINE TRIHYDROCHLORIDE is used as a potential therapeutic agent for the treatment of Parkinson's disease and other neurodegenerative disorders, leveraging its neuroprotective effects.
Used in Anti-Inflammatory and Antioxidant Therapies:
Due to its anti-inflammatory and antioxidant properties, 1-BENZYL-1H-BENZOIMIDAZOL-5-YLAMINE TRIHYDROCHLORIDE is utilized in the development of treatments aimed at reducing inflammation and oxidative stress in various conditions.
Used in Aqueous Solutions for Experimentation and Clinical Applications:
The trihydrochloride form of 1-BENZYL-1H-BENZOIMIDAZOL-5-YLAMINE TRIHYDROCHLORIDE is used to enhance solubility in aqueous solutions, facilitating its application in laboratory research and clinical settings for drug testing and development.

Upstream product

• 100-39-0 benzyl bromide 
• 94-52-0 5-nitrobenzimidazole 

Downstream Products

• 73857-57-5 (1-Benzyl-1H-benzoimidazol-5-yl)-hydrazine; hydrochloride 
• 73857-45-1 3-Benzyl-8-methyl-7-phenyl-3,6-dihydro-imidazo[4,5-e]indole 
• 73857-44-0 3-Benzyl-7,8-dimethyl-3,6-dihydro-imidazo[4,5-e]indole 
• 1026754-71-1 C₂₀H₁₆FN₃O₂S 
• 1026754-75-5 C₂₄H₁₉N₃O₂S 
• 1026754-79-9 C₂₂H₂₁N₃O₂S 
• 1026754-70-0 C₂₀H₁₆BrN₃O₂S 
• 1026754-77-7 C₂₆H₂₁N₃O₂S 
• 1026754-81-3 C₂₅H₂₇N₃O₂S 
• 1026754-68-6 C₂₁H₁₈N₄O₄S 
• 1026754-67-5 C₂₁H₁₈ClN₃O₂S 
• 1026754-86-8 C₂₁H₁₇ClN₄O 
• 1026754-87-9 C₂₁H₁₇N₅O₃ 
• 1026754-72-2 C₂₀H₁₆N₄O₄S 

Relevant academic research and scientific papers

N-1H-Benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists

The Human Pregnane X Receptor (hPXR) is a nuclear receptor that regulates the expression of phase I and phase II drug-metabolizing enzymes, as well as that of drug transporters. Because this receptor plays a critical role in protecting tissues from potentially toxic endo- and xenobiotics, highly active agonists could represent novel therapeutic tools in treating several human diseases. Using an in vitro screening reporter system that allow to characterize hPXR activators and a first step of chemical modifications of an original agonist ligand (C2BA-4, 1-(2-chlorophenyl)-N-[1-(1-phenylethyl)-1H-benzimidazol-5-yl]methanesulf onamide), we identified compounds with a N-1H-benzimidazol-5-ylbenzenesulfonamide scaffold as a potent family of hPXR agonists. Further chemical modifications allowed us to identify enhanced activators, notably N-(1-benzyl-1H-benzimidazol-5-yl)-2,3,4,5,6-pentamethylbenzenesulfonamid e (6n) with an EC50 value in the subnanomolar range. Accordingly to their potent EC50, these compounds induced an efficient protection of hPXR against proteolytic digestion by trypsin even at very low ligand concentrations and were able to induce the expression of the main target genes of hPXR, CYP3A4 and CYP2B6, in primary cultures of human hepatocytes.

TNF-α PRODUCTION INHIBITOR

A novel compound of formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof has a TNF-α production inhibitory activity, it is useful as a method fo